Results 271 to 280 of about 1,541,306 (306)
Some of the next articles are maybe not open access.
Lixisenatide for type 2 diabetes mellitus
Expert Opinion on Investigational Drugs, 2011Type 2 diabetes mellitus (T2DM) is an increasing health problem worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists are an expanding drug class that target several of the pathophysiological traits of T2DM. Lixisenatide is a GLP-1 receptor agonist in development for once-daily treatment of T2DM.Pharmacological, preclinical and clinical evidence
Christensen, Mikkel +3 more
openaire +3 more sources
Pathogenesis of Type 2 Diabetes Mellitus
Archives of Medical Research, 2005The pathological sequence for type 2 diabetes is complex and entails many different elements that act in concert to cause that disease. This review proposes a sequence of events and how they interact by a careful analysis of the human and animal model literature.
openaire +2 more sources
Dyslipidemia in type 2 diabetes mellitus
Current Diabetes Reports, 2007Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus (DM). DM is now recognized as a risk equivalent for coronary heart disease. The lipid profile in patients with type 2 DM is characterized by elevated triglycerides, low levels of high-density lipoprotein cholesterol, and small dense low-density ...
Ramprasad, Gadi, Frederick F, Samaha
openaire +2 more sources
Type 2 diabetes mellitus in adolescents
Current Opinion in Pediatrics, 2000Type 2 diabetes mellitus, a significant cause of adult morbidity and mortality, is being diagnosed more frequently in children and adolescents. Genetic predisposition and environmental factors are important determinants for the expression of this disease.
S T, Callahan, M J, Mansfield
openaire +2 more sources
Hyperuricaemia and type 2 diabetes mellitus
Clinical and Experimental Pharmacology and Physiology, 2018SummaryChoi et al reported the effect of hyperuricaemia on the new‐onset type 2 diabetes mellitus (T2DM). I present three queries. (i) Insulin is considered to stimulate uric acid reabsorption via specific transporter and the effect of hyperuricaemia on the new‐onset T2DM should be evaluated by considering insulin resistance. (ii) There is a limitation
openaire +2 more sources
Genes and Type 2 Diabetes Mellitus
Archives of Medical Research, 2005Type 2 diabetes (T2DM) comprises a group of entities with different genetic causes. In most patients, T2DM results from alterations of various genes, each having a partial and additive effect. The inheritance pattern is thus complex, and environmental factors play an important role in favoring or delaying the expression of the disease.
openaire +2 more sources
Pharmacotherapy of Type 2 Diabetes Mellitus
The Annals of Pharmacotherapy, 2000OBJECTIVE: To review the drug treatments and some of the popular, nontraditional remedies now available for type 2 diabetes mellitus, as well as selected investigational agents; to describe each medication's place in the overall approach to treatment. DATA SOURCES: English-language journals, abstracts, review articles, and newspaper accounts.
M S, Rendell, W R, Kirchain
openaire +2 more sources
Pathogenesis of type 2 diabetes mellitus
Experimental and Clinical Endocrinology & Diabetes, 2001Type 2 diabetes mellitus is a heterogeneous disorder with genetic and acquired components. It is primarily due to impaired insulin secretion in that individuals with genetically impaired beta cell function cannot increase their insulin release sufficiently to compensate for insulin resistance.
J, Dostou, J, Gerich
openaire +2 more sources
Genetics of type 2 diabetes mellitus
Diabetes Research and Clinical Practice, 2005The clinical picture of type 2 diabetes mellitus (T2DM) is formed by impairment in insulin secretion and resistance to insulin action. As a result of intensive efforts of the scientists around the world mutations and polymorphisms in a number of genes were linked with monogenic and polygenic forms of T2DM.
openaire +2 more sources